Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | NPY2R | P49146 | 1/20 | 0.42 |
| ▸ | NCF1 | P14598 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 6/20 | 0.40 |
| ▸ | DRD2 | P14416 | 4/20 | 0.40 |
| ▸ | DRD3 | P35462 | 4/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP5 | P51878 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6696511 | 0.86 | NPY2R (0.45) | NPY2RNCF1DRD4DRD2DRD3 | |
| SCHEMBL1128637 | 0.75 | MEN1 (0.48) | CHRM4DRD4DRD2 | |
| SCHEMBL2509532 | 0.74 | MC4R (0.44) | NCF1ALDH1A1LMNASIGMAR1 | |
| SCHEMBL18580511 | 0.74 | ALDH1A1 (0.48) | ALDH1A1LMNASIGMAR1 | |
| SCHEMBL3584969 | 0.73 | ALDH1A1 (0.47) | NCF1ALDH1A1LMNA | |
| SCHEMBL3757693 | 0.73 | ALDH1A1 (0.45) | ALDH1A1 | |
| SCHEMBL17159943 | 0.72 | CHKA (0.53) | NCF1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL1851425 | 0.72 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL12802187 | 0.71 | NCF1 (0.47) | NCF1ALDH1A1 | |
| SCHEMBL2454168 | 0.71 | DRD4 (0.63) | NCF1DRD4DRD2DRD3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235792-A1 | Serine protease inhibitors compromising a hydrogen-bond acceptor | TRIGEN LIMITED (GB) | 2004-11-25 | — | — | US | disclosed |
| WO-2002057273-A9 | SERINE PROTEASE INHIBITORS COMPRISING A HYDROGEN-BOND ACCEPTOR | TRIGEN LTD (GB) | 2002-11-28 | — | — | WO | disclosed |
| WO-2002057273-A1 | SERINE PROTEASE INHIBITORS COMPRISING A HYDROGEN-BOND ACCEPTOR | TRIGEN LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235792-A1 | Serine protease inhibitors compromising a hydrogen-bond acceptor | SERPINB1, SPINT2, CTRL | CHRM4 4838/4885NPY2R 2744/4885NCF1 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.